male-dr

Leading the world in
early cancer detection research

Our innovative cancer screening
studies mean better outcomes for patients

female-dr

Innovation in cancer research
and development

We are changing the face of cancer detection
and treatment using the latest
advancements in Metabolomics

female-dr

Non-invasive and affordable early
cancer screening and monitoring
solution

90% of cancers are curable if caught early
Your Health is Our Focus!

Early cancer detection research for a better future

BIOMARK’S MISSION

BioMark’s mission is to provide universal access to a new paradigm in cancer diagnostics using metabolomics, dynamic clinical data, radiomics and leveraging the power of machine learning.

WHAT IS A BIOMARKER?

According to the National Cancer Institute a biomarker is “a biological molecule found in blood, other body fluids or tissues that is a sign of a normal or abnormal process or of a condition or disease” (NCI) such as cancer.
Biomarkers typically differentiate an affected patient from a person without the disease. There is tremendous variety of biomarkers which can include:

  • proteins (e.g. an enzyme or receptor)
  • nucleic acids (e.g. a microRNA or other non-coding RNA)
  • antibodies
  • and peptides among other categories

A biomarker can also be a collection of alterations such as gene expression, proteomic, and metabolomic signatures.
Biomarkers can be detected in the circulation (whole blood, serum, or plasma) or excretions or secretions (stool, urine, sputum, or nipple discharge) and thus easily assessed non-invasively and serially. Biomarkers can also be tissue-derived and require either biopsy or special imaging for evaluation.

POTENTIAL CLINICAL USES OF CANCER BIOMARKERS

Biomarkers have many potential applications in oncology including:

  • Estimating risk of cancer
  • Screening for occult primary cancers
  • Distinguishing benign from malignant findings or one type of malignancy from another
  • Monitoring status of the disease either to detect recurrence or determine response or progression to therapy
  • Personalizing a treatment program especially for immunotherapy applications
  • Help in assessing pseudo progression with imaging modalities

VIDEOS: CANCER EDUCATION

VIDEOS: BIO-STREAM DIAGNOSTICS

LATEST POSTS

NEWS RELEASES

Alfred Berkeley Joins BioMark’s Advisory Team

January 11, 2021

Vancouver, British Columbia – (January 11, 2021) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B, OTCMKTS: BMKDF) is glad to announce Alfred Berkeley as a new member of the BioMark’s Advisory team as he will be providing strategic and financial advice to help expand the company’s commercialization effort in the U.S.   Mr. Rashid Ahmed Bux, CEO and President of BioMark Diagnostics says: “We are extremely proud and honored to have Mr. Berkeley join our advisory group at this moment. Mr. Berkeley brings years of experience and a deep […]


READ MORE

STOCK QUOTE

BIOMARK AWARDS, GRANTS, RECOGNITIONS

BioMark has been over the years, funded by various government agencies and Foundation including NRC IRAP, NRC Engage, Genome BC, Government of Manitoba and DFAIT Canada for various projects with active collaboration at University of British Columbia, University of Manitoba, University of Victoria, University of Waterloo, and University of Alberta. Now BioMark is collaborating with Bio banks across Canada and United States to expand our metabolomics study.

Read More